[go: up one dir, main page]

WO2005079767A3 - Moyen de modulation des effets de substances de type opioide - Google Patents

Moyen de modulation des effets de substances de type opioide Download PDF

Info

Publication number
WO2005079767A3
WO2005079767A3 PCT/EP2005/000102 EP2005000102W WO2005079767A3 WO 2005079767 A3 WO2005079767 A3 WO 2005079767A3 EP 2005000102 W EP2005000102 W EP 2005000102W WO 2005079767 A3 WO2005079767 A3 WO 2005079767A3
Authority
WO
WIPO (PCT)
Prior art keywords
opioid
modulation
substances
effects
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/000102
Other languages
English (en)
Other versions
WO2005079767A2 (fr
Inventor
Thomas Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaetsklinikum Muenster
Original Assignee
Universitaetsklinikum Muenster
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaetsklinikum Muenster filed Critical Universitaetsklinikum Muenster
Publication of WO2005079767A2 publication Critical patent/WO2005079767A2/fr
Publication of WO2005079767A3 publication Critical patent/WO2005079767A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'un antagoniste de récepteur d'opiacé pour la préparation d'une composition pharmaceutique destinée à traiter ou à prévenir une insuffisance cardiaque, chez un patient humain, ou un syndrome dysfonctionnel multi-organe chez un patient. L'invention concerne également une méthode pour traiter un patient humain souffrant d'une insuffisance cardiaque ou d'un syndrome de dysfonctionnement multi-organe comprenant l'étape consistant à administrer à un patient, un antagoniste de récepteur d'opiacé, selon un dosage thérapeutiquement efficace.
PCT/EP2005/000102 2004-02-19 2005-01-07 Moyen de modulation des effets de substances de type opioide Ceased WO2005079767A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04003708.7 2004-02-19
EP04003708 2004-02-19

Publications (2)

Publication Number Publication Date
WO2005079767A2 WO2005079767A2 (fr) 2005-09-01
WO2005079767A3 true WO2005079767A3 (fr) 2005-12-01

Family

ID=34878161

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/000102 Ceased WO2005079767A2 (fr) 2004-02-19 2005-01-07 Moyen de modulation des effets de substances de type opioide

Country Status (1)

Country Link
WO (1) WO2005079767A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9561233B2 (en) 2014-03-13 2017-02-07 Demerx, Inc. Use of ibogaine for the treatment of pain
US9592239B2 (en) 2014-09-12 2017-03-14 Demerx, Inc. Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
EP3939570A1 (fr) * 2016-02-18 2022-01-19 Immune Therapeutics, Inc. Naltrexone pour le traitement des maladies auto-immunes et inflammatoires

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
COTTE NATHALIE ET AL: "Prevention and rescue of a mouse model of dilated cardiomyopathy targeting the hyperactive signaling of a Gi-coupled receptor", CIRCULATION, vol. 104, no. 17 Supplement, 23 October 2001 (2001-10-23), & SCIENTIFIC SESSIONS 2001 OF THE AMERICAN HEART ASSOCIATION; ANAHEIM, CALIFORNIA, USA; NOVEMBER 11-14, 2001, pages II.367, XP009053469, ISSN: 0009-7322 *
HIMURA YOSHIHIRO ET AL: "Short-term effects of naloxone on hemodynamics and baroreflex function in conscious dogs with pacing-induced congestive heart failure", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 23, no. 1, 1994, pages 194 - 200, XP009053395, ISSN: 0735-1097 *
IMAI NAOAKI ET AL: "Comparison of cardiovascular effect of mu- and delta-opioid receptor antagonists in dogs with congestive heart failure", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 267, no. 3 PART 2, 1994, pages H912 - H917, XP009053467, ISSN: 0002-9513 *
KINDMAN L A ET AL: "OPIOIDS POTENTIATE CONTRACTILE RESPONSE OF RABBIT MYOCARDIUM TO THE BETA ADRENERGIC AGONIST ISOPROTERENOL", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, vol. 17, no. 1, 1991, pages 61 - 67, XP009053424, ISSN: 0160-2446 *
LIANG C-S ET AL: "THE ROLE OF ENDOGENOUS OPIOIDS IN CONGESTIVE HEART FAILURE EFFECTS OF NALMEFENE ON SYSTEMIC AND REGIONAL HEMODYNAMICS IN DOGS", CIRCULATION, vol. 75, no. 2, 1987, pages 443 - 451, XP002344142, ISSN: 0009-7322 *
LLOBEL F ET AL: "Effects of mu-, delta, and kappa-opioid antagonists in atrial preparations from nonfailing and failing human hearts", GENERAL PHARMACOLOGY, vol. 28, no. 3, 1997, pages 371 - 374, XP002344141, ISSN: 0306-3623 *
OLDROYD K G ET AL: "Activation and inhibition of the endogenous opioid system in human heart failure", BRITISH HEART JOURNAL, vol. 73, no. 1, 1995, pages 41 - 48, XP009053439, ISSN: 0007-0769 *

Also Published As

Publication number Publication date
WO2005079767A2 (fr) 2005-09-01

Similar Documents

Publication Publication Date Title
WO2006015259A3 (fr) Composes et compositions comme modulateurs de recepteurs steroides
WO2006008639A8 (fr) Traitement combine pour malignites non hematologiques par anticorps anti -ogf-1r
WO2002100390A3 (fr) Methode amelioree de traitement du syndrome des facteurs de risque de coronaropathie chez l'etre humain
WO2004073614A3 (fr) Polytherapie servant au traitement de troubles immuno-inflammatoires
WO2004050020A3 (fr) Compositions pharmaceutiques opioïdes améliorées
EP1933833B8 (fr) Therapie pour le traitement de la vessie hyperactive
IL194883A0 (en) Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and paracetamol
WO2006018024A3 (fr) Compositions cosmetiques et pharmaceutiques contenant des inhibiteurs de l'eca et/ou des antagonistes des recepteurs de l'angiotensine ii
WO2004000354A3 (fr) Procede de traitement du syndrome de la lipodystrophie
WO2009050136A3 (fr) Procédé de traitement du syndrome de cushing
WO2008097924A3 (fr) Compositions pharmaceutiques comprenant des analogues du dextrométhorphane pour le traitement de troubles neurologiques
WO2007123848A3 (fr) Préparations thérapeutiques contenant des protéines slrp de classe i modifiées
WO2006036770A3 (fr) Therapie combinatoire dans le traitement de l'obesite
WO2005092009A3 (fr) Inhibiteurs d'acetylcholinesterase et antagonistes de n-methyle-d-aspartate utiles dans le traitement de troubles cognitifs
WO2001054706A3 (fr) Methode de traitement d'affections renales
WO2008016640A3 (fr) Traitement de l'insuffisance cardiaque progressive chronique
WO2005004854A3 (fr) Utilisation de la betaine pour le traitement des arterites
WO2006055352A3 (fr) Methodes de traitement du cancer avec des formulations de composes de platine a base lipipique administrees par voie intraperitoneale
WO2007038506A3 (fr) Methode de traitement de la cachexie
WO2008008882A3 (fr) Modulateur du récepteur des glucocorticoïdes et procédés d'utilisation
WO2004073615A8 (fr) Composes de deazaflavine et leurs methodes d'utilisation
WO2004087880A8 (fr) Composes et leur utilisation dans le traitement du diabete et troubles connexes
WO2006002096A3 (fr) Faibles doses de l-citrulline pour traiter des maladies
WO2005079767A3 (fr) Moyen de modulation des effets de substances de type opioide
WO2005091987A3 (fr) Methode permettant de traiter le syndrome de down

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 35/2005 UNDER (81) ADD "SM"

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase